



Amarin Corporation plc
 Investor Relations Department
 2 Pembroke House, Upper
 Pembroke
 Street 28-32
 Dublin 2
 Ireland

[Visit IR website](#)

[Sign-up for Email alerts](#)

NASDAQ: AMRN

Last Trade:	3.67
Trade Time:	4:00 PM ET Feb 22, 2018
Change:	-0.04 (-1.078%)
Day Range	3.66 - 3.75
52-Week Range	2.85 - 4.60
Volume	957,548

Stock information is provided by eSignal,
 stock charts provided by EDGAR Online.
 Stock data is delayed approximately 20
 minutes.

Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Feb 20, 2018*
[Amarin to Report Fourth Quarter and Full Year 2017 Results and Host Conference Call on February 27th, 2018](#)
- Jan 30, 2018*
[Amarin Prices Public Offering of American Depositary Shares](#)
- Jan 29, 2018*
[Amarin Announces Proposed Public Offering of American Depositary Shares](#)
- Jan 23, 2018*
[Amarin's REDUCE-IT Cardiovascular Outcomes Study Reaches 90% Mark for Reported Primary Events](#)
- Jan 17, 2018*
[Amarin Announces Commencement of VASCEPA® Clinical Development in Mainland China](#)

Upcoming Events [\[View all \]](#)

- Feb 27, 2018 8:00 AM ET*
[Amarin Q4 Results Conference Call](#)
- Financials** [\[View all \]](#)
- [Third Quarter Financial Results](#)
- Mar 1, 2017*
[Annual Report \(10-K\)](#)
- Apr 21, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 1, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017*
[Quarterly Report \(10-Q\)](#)
- May 3, 2017*
[Quarterly Report \(10-Q\)](#)